Interaction of an ordered mesoporous bioactive glass with osteoblasts, fibroblasts and lymphocytes, demonstrating its biocompatibility as a potential bone graft material

Acta Biomaterialia

Volumn 6, Issue 3, 2010, Pages 892-899

  Alcaide, M ^a   Portoles P ^b   Lopez Noriega A ^c,d   Arcos, D ^c,d   Vallet Regi M ^c,d   Portoles M T ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Bioactive glass; Bone graft; Fibroblast; Lymphocyte; Osteoblast

Indexed keywords

BIOACTIVE GLASS; BONE; CELL CULTURE; CELL PROLIFERATION; FIBROBLASTS; OSTEOBLASTS; PHOSPHATE MINERALS; T-CELLS; TISSUE REGENERATION;

AFTER-TREATMENT; BONE GRAFT; BONE GRAFT MATERIALS; BONE TISSUE REGENERATION; FIBROBLAST; IN-VITRO; L929 FIBROBLASTS; MESOPOROUS BIOACTIVE GLASS; ORDERED MESOPOROUS; STRUCTURAL CHARACTERISTICS;

BIOCOMPATIBILITY;

BIOACTIVE GLASS; CALCIUM; CD4 ANTIGEN; GLASS; LACTATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; BONE GRAFT; CELL CYCLE; CELL DAMAGE; CELL STRAIN L 929; CELL STRUCTURE; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOSTASIS; ELUTION; ENZYME RELEASE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; LEACHING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOSYNTHESIS MATERIAL; POROSITY; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE;

EID: 75449083202     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2009.09.008     Document Type: Article

References (38)

1. Hench L.L., and Wilson J. Surface-active biomaterials. Science 226 (1984) 630-636
2. Hench L.L., and Polak J. Third-generation biomedical materials. Science 295 (2002) 1014-1017
3. Hench L.L. Biomaterials. Science 208 (1980) 826-883
4. Vallet-Regí M. Ceramics for medical applications. J Chem Soc, Dalton Trans 2 (2001) 97-108
5. Vallet-Regí M. Revisiting ceramics for medical applications. Dalton Trans 44 (2006) 5211-5220
6. Webster T.J., Ergan C., Doremus R.H., Siegel R.W., and Bizios R. Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials 21 (2000) 1803-1810
7. Vallet-Regí M. Ordered mesoporous materials in the context of drug delivery system and tissue engineering. Chem Eur J 12 (2006) 5934-5943
8. Vallet-Regí M., Ruiz-González L., Izquierdo-Barba I., and González-Calbet J.M. Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem 16 (2006) 26-31
9. Salonen J., Laitinen L., Kaukonen A.M., Tuura J., Björkqvist M., Heikkila T., et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 108 (2005) 362-374
10. Izquierdo-Barba I., Martínez A., Doadrio A.L., Pérez-Pariente J., and Vallet-Regí M. Release evaluation of drugs from ordered tridimensional silica structures. Eur J Pharm Sci 26 (2005) 365-373
11. Yang Q., Wang S.H., Fan P.W., Wang L.F., Di Y., Lin K., et al. PH-Responsive carrier system based on carboxylic acid modified mesoporous silica and polyelectrolyte for drug delivery. Chem Mater 17 (2005) 5999-6003
12. Vallet-Regí M., Balas F., and Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 46 (2007) 7548-7558
13. Vallet-Regí M., Izquierdo-Barba I., Ramila A., Pérez-Pariente J., Babonneau F., and González-Calbet J.M. Phosphorous-doped MCM-41 as bioactive material. Solid State Sci 7 (2005) 233-237
14. Yan X.X., Yu C.Z., Zhou X.F., Tang J.W., and Zhao D.Y. Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angew Chem Int Ed 43 (2004) 5980-5984
15. Yan X.X., Deng H.X., Huang X.H., Lu G.Q., Quiao S.Z., Zhao D.Y., et al. Mesoporous bioactive glasses: I. Synthesis and structural characterization. J Non-Cryst Solids 351 (2005) 3209-3217
16. López-Noriega A., Arcos D., Izquierdo-Barba I., Sakamoto Y., Terasaki O., and Vallet-Regí M. Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem Mater 18 (2006) 3137-3144
17. + T cell line is activated by syngeneic antigen presenting cells in the absence of antigen. Cell Immunol 164 (1995) 265-278
18. Kaye J., Porcelli S., Tite J., Jones B., and Janeway Jr. C.A. Both a monoclonal antibody and antisera specific for determinants unique to individual cloned helper T cell lines can substitute for antigen and antigen-presenting cells in the activation of T cells. J Exp Med 158 (1983) 836-856
19. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
20. Carlisle E.M. Silicon: a possible factor in bone calcification. Science 167 (1970) 179
21. Carlisle E.M. Silicon: a requirement in bone formation independent of vitamin D1. Calc Tissue Int 33 (1981) 27
22. ® 45S5 dissolution. J Biomed Mater Res 55 (2001) 151-157
23. Xynos I.D., Edgar A.J., Buttery L.D.K., Hench L.L., and Polar J.M. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein síntesis. Biochem Biophys Res Commun 276 (2000) 461-465
24. Facompré M., Wattez N., Kluza J., Lansiaux A., and Bailly C. Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide. Mol Cell Biol Res Commun 4 (2000) 37-42
25. Nishimura D., Ishikawa H., Matsumoto K., Shibata H., Motoyoshi Y., Fukuta M., et al. DHMEQ, a novel NF-kB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol 29 (2006) 713-719
26. Serrano M.C., Pagani R., Peña J., and Portolés M.T. Transitory oxidative stress in L929 fibroblasts cultured on poly(ε-caprolactone) films. Biomaterials 26 (2005) 5827-5834
27. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59 (1979) 527-604
28. Henseley K., Robinson K.A., Gabbita S.P., Salsman S., and Floyd R.A. Reactive oxygen species, cell signalling and cell injury. Free Radic Biol Med 28 (2000) 1456-1462
29. Richter C., Gogvadze V., Laffranchi R., Schlapbach R., Schnizer M., Suter M., et al. Oxidants in mitochondria: from physiology to disease. Biochim Biophys Acta 1271 (1995) 67-74
30. Burow S., and Valet G. Flow-cytometric characterization of stimulation, free radical formation, peroxidase activity and phagocytosis of human granulocytes with 2,7-dichlorofluorescein (DCF). Eur J Cell Biol 43 (1987) 128-133
31. Olmo N., Martin A.I., Salinas A.J., Turnay J., Vallet-Regí M., and Lizarbe M.A. Bioactive sol-gel glasses with and without a hydroxycarbonate apatite layers as substrates for osteoblast cell adhesion and proliferation. Biomaterials 24 (2003) 3383-3393
32. Ramires P.A., Wennerberg A., Johanson C.B., Cosentino G., Tundo S., and Milella E. Biological behaviour of sol-gel coated dental implants. J Mater Sci Mater Med 14 (2003) 539-545
33. Andrade A.L., Valério P., Goes A.M., Leite M.F., and Domingues R.Z. Influence of morphology on in vitro compatibility of bioactive glasses. J Non-Cryst Solids 352 (2006) 3508-3511
34. Kim S.T., and Kim C.K. Water-soluble chitosan-based antisense oligodeoxynucleotide of interleukin-5 for treatment of allergic rhinitis. Biomaterials 28 (2007) 3360-3368
35. Díez-Orejas R., Ballester S., Feito M.J., Ojeda G., Criado G., Ronda M., et al. Genetic and immunochemical evidence for CD4-dependent association of p56lck with the alpha beta T-cell receptor (TCR): regulation of TCR-induced activation. EMBO J 13 (1994) 90-99
36. Rojo J.M., and Janeway Jr. C.A. The biologic activity of anti-T cell receptor V region monoclonal antibodies is determined by the epitope recognized. J Immunol 140 (1988) 1081-1088
37. Bourke P.F., van Leeuwen B.H., Campbell H.D., and Young I.G. Localization of the inducible enhancer in the mouse interleukin-5 gene that is responsive to T-cell receptor stimulation. Blood 85 (1995) 2069-2077
38. Yoshino T., Ishikawa J., Ohga K., Morokata T., Takezawa R., Morio H., et al. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. Eur J Pharmacol 560 (2007) 225-233